
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …

Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

